| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cross-sector, multidisciplinary approach to lipid optimisation
|
Jones, M.
|
|
|
54 |
S1 |
p. S10
|
artikel
|
| 2 |
Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
|
Ofagbor, E.
|
|
|
54 |
S1 |
p. S10-S11
|
artikel
|
| 3 |
Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in South London
|
Ayoub, Aya
|
|
|
54 |
S1 |
p. S7
|
artikel
|
| 4 |
Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
|
David, A.
|
|
|
54 |
S1 |
p. S4
|
artikel
|
| 5 |
Evolocumab & Inclisiran dual therapy for further LDL lowering in a very high cardiovascular risk Familial Hypercholesterolaemia patient with heterozygous gain of function PCSK9 mutation
|
Gingell, R.
|
|
|
54 |
S1 |
p. S4-S5
|
artikel
|
| 6 |
Familial Chylomicronaemia Syndrome (FCS) Compared to Multifactorial Chylomicronaemia Syndrome (MCS) – Lessons learnt from United Kingdom FCS Registry
|
Bashir, B.
|
|
|
54 |
S1 |
p. S4
|
artikel
|
| 7 |
Familial Chylomicronaemia Syndrome (FCS) Score Validation in United Kingdom FCS Registry: Can Additional Variables Improve the FCS Score Performance?
|
Bashir, B.
|
|
|
54 |
S1 |
p. S8
|
artikel
|
| 8 |
HEART UK 2023 Moderated Posters
|
|
|
|
54 |
S1 |
p. S11
|
artikel
|
| 9 |
HEART UK 2023 Oral Presentations
|
|
|
|
54 |
S1 |
p. S5-S6
|
artikel
|
| 10 |
How many FH genetic tests were performed by the UK Genetic Laboratory Hubs in 2022?
|
Humphries, S.E.
|
|
|
54 |
S1 |
p. S9
|
artikel
|
| 11 |
How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
|
Humphries, S.E.
|
|
|
54 |
S1 |
p. S3
|
artikel
|
| 12 |
Impact of a pharmacist-led clinic in optimising lipid therapy for secondary prevention in vascular and diabetic foot patients
|
Hart, M.
|
|
|
54 |
S1 |
p. S5
|
artikel
|
| 13 |
Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study
|
Masana, L.
|
|
|
54 |
S1 |
p. S9
|
artikel
|
| 14 |
Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia
|
Cegla, J.
|
|
|
54 |
S1 |
p. S2-S3
|
artikel
|
| 15 |
Patient demographics and clinical characteristics among patients with a premature myocardial infarction and lipoprotein(a) measurement: a retrospective analysis of the South Tyneside and Sunderland NHS Foundation Trust in the UK
|
Connell, E.
|
|
|
54 |
S1 |
p. S2
|
artikel
|
| 16 |
Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
|
Gratton, J.
|
|
|
54 |
S1 |
p. S3
|
artikel
|
| 17 |
Should the Sampson LDL cholesterol equation replace the Friedewald equation in routine clinical practice? A comparison of three equations against a beta quantification method
|
Abbas, M.
|
|
|
54 |
S1 |
p. S7
|
artikel
|
| 18 |
Statin treatment is associated with greater hyperglycaemic response to a glucagon challenge
|
Mamidi, R.
|
|
|
54 |
S1 |
p. S9-S10
|
artikel
|
| 19 |
Title Page
|
|
|
|
54 |
S1 |
p. S1
|
artikel
|
Tijdschrift beschrijving